Search

for
Search:

Research

5 / 1000+ results

research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).

2 citations , May 2011 in “Journal of Clinical Oncology”

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

research Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy

1 citations , June 2007 in “Journal of Clinical Oncology”

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

Multicentric Parallel Phase II Trial of the Polo-Like Kinase 1 Inhibitor BI 2536 in Patients With Advanced Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, and Melanoma. The First Protocol of the European Organization for Research and Treatment of Cancer Network of Core Institutes

research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

93 citations , May 2010 in “European Journal of Cancer”

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

research THU0301 A Phase II Trial of Retinoids on Lupus Nephritis in A Single Center

1 citations , June 2016 in “Annals of the rheumatic diseases”

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

March 2026 in “British Journal of Dermatology”

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

View more "phase ii trials" in research →

Community Join

5 / 1000+ results

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community About Pyrilutamide Phase II US Trial

in Research/Science 11 upvotes 3 years ago

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

90 upvotes 3 years ago

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

community GT20029 - Promising phase II results

16 upvotes 2 years ago

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

community KX-826 1% Phase II Results from China Just Dropped

37 upvotes 1 year ago

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

View more "phase ii trials" in community →

Learn

6 / 33 results

learn GT20029

research compound made to degrade androgen receptors in scalp

When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.

learn Clascoterone

Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.

learn HMI-115

much-hyped research compound targeting prolactin receptor in scalp

learn Hair Multiplication

extract, clone, and reinsert your own hair cells

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn Overview

View more "phase ii trials" in learn →

Clinics

1 / 13 results

Hair Systems
Mane PhaseRancho Cucamonga, CA · US

Experts

— no results

Try a deeper search in experts →